Login
Companies $HURA
$1.35 +$0.02 (1.5%) After hours
TuHURA Biosciences, Inc. logo

TuHURA Biosciences, Inc.

tuhurabio.com

What Do They Do?

Develops immune-based cancer drug candidates for patients whose cancers resist immunotherapy.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +10% (Loss)
vs −$7.1M in Q3 FY2025

Pipeline focus The older report described chemotherapy and light-activated therapy candidates; the latest focuses on immune-based treatments, including an innate immune agonist, a VISTA-inhibiting antibody and immune-modulating antibody-drug conjugates.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support